{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:58:20Z","timestamp":1790470700397,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.01.017","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T16:35:21Z","timestamp":1579019721000},"page":"4135-4141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10\u201311 September 2019"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-6709","authenticated-orcid":false,"given":"Kolawole","family":"Salami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-St\u00e9phane","family":"Gsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebola","family":"Olayinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diadie","family":"Maiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Formenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasee","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.017_b0005","unstructured":"World Health Organization. Lassa fever research and development roadmap 2018:1\u201318. http:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/LassaFever_Draft_Roadmap_publiccomment_MAY2018.pdf (accessed November 15, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0010","unstructured":"NCDC. Nigeria centre for disease control; 2018. https:\/\/ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=An update of Lassa fever outbreak in Nigeria (accessed April 9, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0015","unstructured":"NCDC. Nigeria centre for disease control projects; 2019. https:\/\/ncdc.gov.ng\/news\/165\/decline-in-lassa-fever-cases-as-ncdc-sustains-intensive-response%0Ahttps:\/\/ncdc.gov.ng\/projects (accessed November 15, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0020","unstructured":"World Health Organization. WHO target product profile for lassa virus vaccine. http:\/\/WwwWhoInt\/Csr\/Research-and-Development\/List_of_pathogens\/En\/2017. http:\/\/www.who.int\/csr\/research-and-development\/list_of_pathogens\/en\/ (accessed July 3, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0025","unstructured":"WHO. Efficacy trials of Lassa Vaccines: endpoints, trial design, site selection. Effic. trials Lassa Vaccines endpoints, trial Des. site Sel., Geneva: WHO; 2018."},{"key":"10.1016\/j.vaccine.2020.01.017_b0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coviro.2019.07.006","article-title":"A review of Lassa fever vaccine candidates","volume":"37","author":"Salami","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2020.01.017_b0035","unstructured":"THEMIS. Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate n.d. https:\/\/www.pharmaceutical-business-review.com\/news\/themis-mv-lasv-lassa-fever-vaccine\/ (accessed November 11, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0040","unstructured":"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Tech Rep 2004:35\u2013102. http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/clinical_evaluation\/en\/ (accessed November 15, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article","author":"Hallam","year":"2018","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.01.017_b0050","doi-asserted-by":"crossref","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus\u2013based vaccines against lassa and ebola viruses","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.017_b0055","unstructured":"edctp. Vaccines against Lassa virus disease \u2013 Joint call with the coalition for epidemic preparedness innovations (CEPI) - EDCTP n.d. http:\/\/www.edctp.org\/call\/vaccines-against-lassa-virus-diseases-joint-call-with-the-coalition-for-epidemic-preparedness-innovations-cepi\/ (accessed November 12, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0060","article-title":"Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings","volume":"4","author":"Mazzola","year":"2019","journal-title":"BMJ Glob Heal"},{"key":"10.1016\/j.vaccine.2020.01.017_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2016.11.001","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein","author":"Cheng","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.01.017_b0070","unstructured":"FIND. Diagnostic capacity to combat Lassa fever - FIND n.d. https:\/\/www.finddx.org\/pan-prep\/dx-capacity-lassa\/ (accessed October 1, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0075","doi-asserted-by":"crossref","first-page":"e01896","DOI":"10.1128\/mBio.01896-18","article-title":"Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following lassa virus exposure in cynomolgus macaques","volume":"9","author":"Cashman","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2020.01.017_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA animal rule","author":"Beasley","year":"2016","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.01.017_b0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2168479017694850","article-title":"Overview of FDA\u2019s expanded access program for investigational drugs","volume":"51","author":"Jarow","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.vaccine.2020.01.017_b0090","unstructured":"WHO. WHO | emergency use assessment and listing (EUAL) procedure for IVDs. WHO 2017. https:\/\/www.who.int\/diagnostics_laboratory\/eual\/emergency\/en\/ (accessed October 1, 2019)."},{"key":"10.1016\/j.vaccine.2020.01.017_b0095","unstructured":"African Vaccine Regulatory Forum (AVAREF). New plan to accelerate product development and access in Africa. Entebbe; 2018."},{"key":"10.1016\/j.vaccine.2020.01.017_b0100","unstructured":"WHO. Assessing the programmatic suitability of vaccine candidates for WHO prequalification. Geneva; 2014."},{"key":"10.1016\/j.vaccine.2020.01.017_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002748","article-title":"Lassa fever in post-conflict sierra leone","volume":"8","author":"Shaffer","year":"2014","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:34Z","timestamp":1759401814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":21,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20300323"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10\u201311 September 2019","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}